Mga Batayang Estadistika
| CIK | 1385228 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BIND Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 25, 2019 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: DNIB UNWIND, INC. (f/k/a BIND THERAPEUTICS, INC.), et al.,1 Post-Effective Date Debtors. x : : : : : : : : Chapter 11 Case No. 16-11084 (BLS) (Jointly Administered) - x NOTICE OF FINAL DISTRIBUTION PLEASE TAKE NOTICE that (i) on September 14, 2016, the Debtors filed the Debtors’ Amended Combined Disclo |
|
| November 25, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 25, 2019 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation) (Commi |
|
| April 26, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2018 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organiz |
|
| April 26, 2018 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: DNIB UNWIND, INC. (f/k/a BIND THERAPEUTICS, INC.), et al.,1 Post-Effective Date Debtors. x : : : : : : x Chapter 11 Case No. 16-11084 (BLS) (Jointly Administered) NOTICE OF DISTRIBUTION PLEASE TAKE NOTICE that (i) on September 14, 2016, the Debtors filed the Debtors’ Amended Combined Disclosure Statement |
|
| February 12, 2018 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - X In re: : Chapter 11 : DNIB UNWIND, INC. (f/k/a BIND : Case No. 16-11084 (BLS) THERAPEUTICS, INC.), et al.1 : : (Jointly Administered) Post-Effective Date Debtors. : : : - X THIRD STATUS REPORT REGARDING HOLDERS OF DNIB STOCK PURSUANT TO THE DEBTORS? PLAN OF LIQUIDATION The Trustee (the ?Trustee?) of the DNI |
|
| February 12, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d536061d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2018 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorp |
|
| September 26, 2017 |
EX-99.1 2 d396418dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x In re: : Chapter 11 : DNIB UNWIND, INC. (f/k/a BIND : Case No. 16-11084 (BLS) THERAPEUTICS, INC.), et al.,1 : : (Jointly Administered) Post-Effective Date Debtors. : : : x NOTICE OF DISTRIBUTION PLEASE TAKE NOTICE that (i) on September 14, 2016, the Debtors filed the Debtors’ Amend |
|
| September 26, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2017 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organiza |
|
| September 26, 2017 |
EX-99.2 3 d396418dex992.htm EX-99.2 Exhibit 99.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x In re: : Chapter 11 : DNIB UNWIND, INC. (f/k/a BIND : Case No. 16-11084 (BLS) THERAPEUTICS, INC.), et al.1 : : (Jointly Administered) Post-Effective Date Debtors. : : : x SECOND STATUS REPORT REGARDING DISTRIBUTIONS TO HOLDERS OF DNIB STOCK PURSUANT TO THE DEBTORS’ PLAN OF LIQUIDAT |
|
| April 24, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2017 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organization |
|
| April 24, 2017 |
EX-99.1 2 d346016dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x In re: : Chapter 11 : DNIB UNWIND, INC. (f/k/a BIND : Case No. 16-11084 (BLS) THERAPEUTICS, INC.), et al.1 : : (Jointly Administered) Post-Effective Date Debtors. : : : x STATUS REPORT REGARDING DISTRIBUTIONS TO HOLDERS OF DNIB STOCK PURSUANT TO THE DEBTORS’ PLAN OF LIQUIDATION The |
|
| February 13, 2017 |
EX-99.1 2 d350024dex991.htm EX1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 13, 2017 |
|
| February 13, 2017 |
BINDQ / DNIB Unwind, Inc. / Flagship Ventures Fund 2004 L P - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DNIB Unwind, Inc. (f/k/a BIND Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05548N107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 8, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2017 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organ |
|
| February 8, 2017 |
EX-99.1 Exhibit 99.1 Case 16-11084-BLS Doc 583 Filed 02/03/17 Page 1 of 3 OFFICE OF THE UNITED STATES TRUSTEE - REGION 3 POST-CONFIRMATION QUARTERLY SUMMARY REPORT This Report is to be submitted for all bank accounts that are presently maintained by the post confirmation debtor. Debtor?s Name: DNIB Unwind, Inc. and DNIB Subsidiary Bank: NY Signature Bank Corporation (DNIB Liquidation Trust) Bankru |
|
| January 30, 2017 |
FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36072 DNIB UNWIND, INC. (Exact name of Registrant as specified in |
|
| January 18, 2017 |
BINDQ / DNIB Unwind, Inc. / DHK Investments, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* DNIB UNWIND, INC. (formerly known as BIND Therapeutics, Inc.) (Name of Issuer) Common Stock, $0.0001 par value per share 05548N107 (Title of class of securities) (CUSIP number) December 31, 2016 (Date of Event Which Requires Filing of this Sta |
|
| January 18, 2017 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 1 to the Statement on Schedule 13G, dated January 18, 2017, with respect to the shares of DNIB Unwind, Inc., formerly known as BIND Therapeutics, Inc., Common Stock, $.0001 par value, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accorda |
|
| December 21, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organizat |
|
| November 29, 2016 |
8-K 1 d304774d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 23, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of |
|
| November 2, 2016 |
EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In re Bind Therapeutics, Inc. Case No. 16-11084 (BLS) Reporting Period: Sep 1 - 30, 2016 MONTHLY OPERATING REPORT File with Court and submit copy to United States Trustee within 20 days after end of month Submit copy of report to any official committee appointed in the case, REQUIRED DOCUMENTS Form No. Document Attached Expla |
|
| November 2, 2016 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organ |
|
| October 14, 2016 |
S-8 POS 1 d267777ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 14, 2016 Registration No. 333-191297 Registration No. 333-194792 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-191297) (POST-EFFECTIVE |
|
| October 14, 2016 |
POS AM As filed with the Securities and Exchange Commission on October 14, 2016 Registration No. |
|
| October 14, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on October 14, 2016 Registration No. |
|
| October 11, 2016 |
DNIB Unwind FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organ |
|
| October 3, 2016 |
EX-99.1 Exhibit 99.1 In re Bind Therapeutics, Inc. Case No. 16-11084 (BLS) Debtor Reporting Period: Aug 31, 2016 SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS Amounts reported should be per the debtor?s books, not the bank statement. The beginning cash should be the ending cash from the prior month or, if this is the first report, the amount should be the balance on the date the petition was filled. |
|
| October 3, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 d227054d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of inco |
|
| September 27, 2016 |
8-K 1 d265486d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of |
|
| September 27, 2016 |
EX-99.1 3 d265486dex991.htm EXHIBIT 99.1 Exhibit 99.1 Case 16-11084-BLS Doc 457 Filed 09/26/16 Page 1 of 33 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x In re: DNIB UNWIND, INC. (f/k/a BIND THERAPEUTICS, INC.), et al.,1 Debtors. : : : : : : : Chapter 11 Case No. 16-11084 (BLS) (Jointly Administered) Re: Docket Nos. 354, 355, 356, 415, 416, 420, 422 & 423 x FINDINGS OF FACT, |
|
| September 27, 2016 |
EX-2.1 2 d265486dex21.htm EXHIBIT 2.1 Exhibit 2.1 Case 16-11084-BLS Doc 415 Filed 09/14/16 Page 1 of 101 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x In re: : Chapter 11 : DNIB UNWIND, INC. (f/k/a BIND : Case No. 16-11084 (BLS) THERAPEUTICS, INC.), et al.1, : : (Jointly Administered) Debtors. : : : x DEBTORS’ AMENDED COMBINED DISCLOSURE STATEMENT AND CHAPTER 11 PLAN OF LIQU |
|
| September 14, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organiza |
|
| September 7, 2016 |
SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In re Bind Therapeutics, Inc. Case No 16-11084 (BLS) Reporting Period: July 1 - 31, 2016 MONTHLY OPERATING REPORT File with Court and submit copy to United States Trustee within 20 days after end of month Submit copy of report to any official committee appointed in the case REQUIRED DOCUMENTS Form No. Document Attached Explan |
|
| September 7, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 d254410d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 1, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incor |
|
| August 30, 2016 |
8-K 1 d244631d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorpo |
|
| August 15, 2016 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: DNIB UNWIND, INC. (f/k/a BIND THERAPEUTICS, INC.), et al.1, Debtors. x : : : : : : : : Chapter 11 Case No. 16-11084 (BLS) (Jointly Administered) Hearing Date: September 21, 2016 at 1:00 p.m. (ET) Objection Deadline: September 14, 2016 at 4:00 p.m. (ET) - x DEBTORS’ COMBINED DISCLOSURE STATEMENT AND CHAPTER 11 |
|
| August 15, 2016 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - In re: DNIB UNWIND, INC. (f/k/a BIND THERAPEUTICS, INC.), et al.1, Debtors. x : : : : : : : : Chapter 11 Case No. 16-11084 (BLS) (Jointly Administered) Hearing Date: September 21, 2016 at 1:00 p.m. (ET) Objection Deadline: September 14, 2016 at 4:00 p.m. (ET) - x DEBTORS’ COMBINED DISCLOSURE STATEMENT AND CHAPTER 11 |
|
| August 15, 2016 |
BIND Therapeutics FORM 10-Q (Quarterly Report) 10-Q 1 bind-10q20160630.htm FORM 10-Q . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| August 9, 2016 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36072 CUSIP NUMBER 233242 106 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K |
|
| August 4, 2016 |
BINDQ / DNIB Unwind, Inc. / RUSNANO - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* DNIB Unwind, Inc. (f/k/a/ Bind Therapeutics, Inc.) (Name of Issuer) Common Stock, par value $.0001 per share (Title of Class of Securities) 05548N107 (CUSIP Number) Joint Stock Company “RUSNANO” Prospect 60-letiya Oktyabrya 10a 117036 Moscow Russian Federatio |
|
| August 2, 2016 |
8-K/A 1 d233881d8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other ju |
|
| August 2, 2016 |
EX-10.1 Exhibit 10.1 e-mail: [email protected] July 29, 2016 Andrew Hirsch President and CEO BIND Therapeutics, Inc. 325 Vassar Street Cambridge, MA 02139 Re: Development Specialists, Inc. (?DSI?) Engagement Agreement Dear Mr. Hirsch: Please accept this letter as our firm?s (?DSI?s?) formal written agreement to provide consulting services to BIND Therapeutics, Inc. and BIND Biosciences Security Corp |
|
| August 1, 2016 |
8-K 1 d188164d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2016 DNIB UNWIND, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of inc |
|
| August 1, 2016 |
CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION BIND THERAPEUTICS, INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF BIND THERAPEUTICS, INC. BIND Therapeutics, Inc. (hereinafter called the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. That the name of this corporation is BIND Therapeutics, Inc., and that this |
|
| July 28, 2016 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND BETWEEN PFIZER, INC. as Purchaser, and BIND THERAPEUTICS, INC. as Seller Dated as of July 1, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 1.1 Certain Definitions 1 1.2 Terms Defined Elsewhere in this Agreement 11 ARTICLE II. ACQUISITION AND TRANSFER OF ASSETS; ASSUMPTION OF LIABILITIES 13 2.1 Acquisition and Transfer of A |
|
| July 28, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| July 6, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or org |
|
| July 6, 2016 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND BETWEEN PFIZER, INC. as Purchaser, and BIND THERAPEUTICS, INC. as Seller Dated as of July 1, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 1.1 Certain Definitions 1 1.2 Terms Defined Elsewhere in this Agreement 11 ARTICLE II. ACQUISITION AND TRANSFER OF ASSETS; ASSUMPTION OF LIABILITIES 13 2.1 Acquisition and Transfer of A |
|
| June 22, 2016 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| June 17, 2016 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ |
|
| June 17, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| May 19, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or org |
|
| May 11, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organization |
|
| May 9, 2016 |
BIND Therapeutics 10-Q (Quarterly Report) bind-10q20160331.htm . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-360 |
|
| May 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or orga |
|
| May 9, 2016 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update Company does not anticipate disruption in operations under Chapter 11 protection CAMBRIDGE, Mass., May 9, 2016 ? BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS?, today reported financial res |
|
| May 6, 2016 |
8-K 1 d353680d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incor |
|
| May 6, 2016 |
EX-99.1 2 d353680dex991.htm EX-99.1 EXHIBIT 99.1 Case 16-11084-BLS Doc 35 Filed 05/03/16 Page 1 of 5 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE X In re: : Chapter 11 : BIND THERAPEUTICS, INC., et al.,1 : Case No. 16-11084 (BLS) : Debtors. : (Jointly Administered) : X Re: Docket No. 10 INTERIM ORDER ESTABLISHING NOTICE AND HEARING PROCEDURES FOR TRADING IN EQUITY SECURITIES |
|
| May 2, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organi |
|
| April 29, 2016 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2016 |
DEF 14A 1 d119408ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the app |
|
| April 6, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| March 24, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or o |
|
| March 15, 2016 |
BIND Therapeutics 10-K (Annual Report) bind-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36072 BIND The |
|
| March 15, 2016 |
BIND Therapeutics FORM 8-K (Current Report/Significant Event) FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or o |
|
| March 15, 2016 |
EX-99.1 2 d115717dex991.htm EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform — Management to host conference call today at 8:30 a.m. ET to provide business update and review fourth quarter and fiscal year 2015 financial res |
|
| March 15, 2016 |
Subsidiaries of BIND Therapeutics, Inc.: EX-21.1 2 bind-ex2116.htm EX-21.1 Exhibit 21.1 Subsidiaries of BIND Therapeutics, Inc.: Name Jurisdiction of Organization BIND (RUS) LLC Russia BIND Biosciences Security Corporation Massachusetts |
|
| February 12, 2016 |
BINDQ / DNIB Unwind, Inc. / CAPITAL VENTURES INTERNATIONAL - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* BIND Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 05548N107 (CUSIP Number) December 31, 201 |
|
| January 27, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| January 7, 2016 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2016 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| December 17, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d107079d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdicti |
|
| December 17, 2015 |
EX-10.1 EXHIBIT 10.1 Confidential Treatment Requested by BIND Therapeutics, Inc. THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT This THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (this ?Amendment?) is entered into as of December 8, 2015 (the ?Third Amendment Effective Date?), by and between BIND Therapeutics, Inc. (as successor in interest to BIND Biosciences, Inc.) |
|
| December 14, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or org |
|
| November 18, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 18, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation o |
|
| November 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36072 BIND Therapeut |
|
| November 2, 2015 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update ? iNSITE 1 trial on track for stage 1 data by year-end; iNSITE 2 on track for stage 1 data in 1H 2016 for treatment of rare tumor types ? ? Progress continues in developing next-generation Accurin products for multiple therapeutic areas ? CAMBRIDGE, Mass., November 2, 2015 ? BIND Thera |
|
| November 2, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| October 14, 2015 |
8-K 1 d38842d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction |
|
| September 24, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation |
|
| August 6, 2015 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update ? Preliminary interim data from iNSITE 1 clinical trial remains on track for fourth quarter of 2015 ? ? Second Accurin candidate, AZD-2811, to enter clinic in fourth quarter of 2015 ? ? Progress made developing next-generation Accurin product concepts for multiple therapeutic areas ? |
|
| August 6, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organi |
|
| August 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d948489d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| June 23, 2015 |
BIND Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| June 22, 2015 |
BIND Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| June 10, 2015 |
BIND Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or org |
|
| May 7, 2015 |
Exhibit 10.4 Confidential Treatment Requested by BIND Therapeutics, Inc. SECOND AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT This SECOND AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of March 31, 2015 (the “Second Amendment Effective Date”), by and between BIND Therapeutics, Inc. (as successor in interest to BIND Biosciences, Inc.) (“BIND” |
|
| May 7, 2015 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-199105 PROSPECTUS SUPPLEMENT (To Prospectus dated October 15, 2014) $40,000,000 Common Stock We have entered into a Sales Agreement, or sales agreement, with Cowen and Company, LLC, or Cowen, dated October 1, 2014, relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance wit |
|
| May 7, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d920562d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incor |
|
| May 7, 2015 |
Exhibit 4.2 EXECUTION VERSION WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”) is dated February 10, 2015, between BIND Therapeutics, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, acting as warrant agent (the “Warrant Agent”). WHEREAS, the Company proposes to issue warrants (the “Warrants”) to acquire up to 2,243,478 shares, subject to a |
|
| May 7, 2015 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update ? First Patient Dosed in Squamous Histology Cohort and Enrollment On-track in KRAS Mutant Cohort of iNSITE 1 Clinical Trial in NSCLC ? ? Milestone Achieved in Collaboration with AstraZeneca and Second Accurin Candidate, AZD2811, Expected to Enter Clinic in 2H2015? ? Management to host |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d890886d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| April 27, 2015 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2015 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 2, 2015 |
BIND Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| March 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 d837520d10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| March 11, 2015 |
BIND Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or o |
|
| March 11, 2015 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results ? Enrollment Underway in Phase 2 iNSITE 1 Trial for BIND-014 in KRAS Mutant or Squamous Histology Non-Small Cell Lung Cancer; Initial Clinical Data Reported as Early as 4th Quarter 2015 - ? Management to host conference call today at 8:30 a.m. EDT ? CAMBRIDGE, Mass., March 11, 2015 ? BIND Therapeutic |
|
| March 11, 2015 |
Subsidiaries of BIND Therapeutics, Inc.: Exhibit 21.1 Subsidiaries of BIND Therapeutics, Inc.: Name Jurisdiction of Organization BIND (RUS) LLC Russia BIND Biosciences Security Corporation Massachusetts |
|
| March 10, 2015 |
8-K 1 d889129d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction o |
|
| March 10, 2015 |
Separation Agreement and Release EX-10.1 Exhibit 10.1 Separation Agreement and Release This Separation Agreement and Release (?Agreement?) is made by and between Scott Minick (?Executive?) and BIND Therapeutics, Inc. (the ?Company?) as of the Effective Date defined below. WHEREAS, Executive and the Company are parties to a letter agreement dated January 11, 2010 regarding Executive?s employment offer (the ?Offer Letter?), a lette |
|
| March 10, 2015 |
rrd381341431956.html POWER OF ATTORNEY Christopher Lindblom With respect to holdings of and transactions in securities issued by BIND Therapeutics, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act |
|
| March 10, 2015 |
EX-10.2 3 d889129dex102.htm EX-10.2 Exhibit 10.2 BIND Therapeutics, Inc. 325 Vassar Street Cambridge, MA 02139 www.bindtherapeutics.com phone 617.491.3400 fax 617.491.0351 March 10, 2015 HAND DELIVERED Re: Employment Terms Dear Andrew: Reference is made to (i) that certain employment offer letter, dated as of June 19, 2012, by and between BIND Therapeutics, Inc., formerly known as BIND Biosciences |
|
| February 13, 2015 |
BINDQ / DNIB Unwind, Inc. / CAPITAL VENTURES INTERNATIONAL - SC 13G Passive Investment CUSIP No. 05548N107 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* BIND Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 05548N107 (CUSIP N |
|
| February 11, 2015 |
BINDQ / DNIB Unwind, Inc. / Arch Venture Fund VII LP - BIND THERAPEUTICS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIND Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05548N107 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2015 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION BIND Therapeutics, Inc. 3,739,130 Units Each Consisting of One Share of Common Stock and 0.60 of a Warrant to Purchase One Share of Common Stock UNDERWRITING AGREEMENT February 5, 2015 COWEN AND COMPANY, LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York |
|
| February 10, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| February 10, 2015 |
[FORM OF WARRANT AGREEMENT] WARRANT AGREEMENT EX-4.1 3 d867582dex41.htm EX-4.1 Exhibit 4.1 [FORM OF WARRANT AGREEMENT] WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”) is dated February 10, 2015, between BIND Therapeutics, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, acting as warrant agent (the “Warrant Agent”). WHEREAS, the Company proposes to issue warrants (the “Warrants”) to a |
|
| February 10, 2015 |
EX-4.2 Exhibit 4.2 [FORM OF WARRANT CERTIFICATE] [UNLESS THIS GLOBAL WARRANT CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPR |
|
| February 6, 2015 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-199105 PROSPECTUS SUPPLEMENT (To Prospectus dated October 15, 2014) 3,739,130 Units Each Consisting of One Share of Common Stock and 0.60 of a Warrant to Purchase One Share of Common Stock We are offering 3,739,130 units, with each unit consisting of one share of our common stock and 0.60 of a warrant to purchase one sha |
|
| February 5, 2015 |
Subject to Completion, dated February 4, 2015 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-199105 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sel |
|
| February 4, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| January 23, 2015 |
EX-4.1 Exhibit 4.1 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SA |
|
| January 23, 2015 |
FIRST AMENDMENT AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of January 23, 2015, by and between HERCULES TECHNOLOGY III, L.P. (“Lender”) and BIND THERAPEUTICS, INC. (“Borrower”). RECITALS Borrower and Lender are parties to that certain Amended and Restated Loa |
|
| January 23, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| January 7, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2015 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or organ |
|
| January 7, 2015 |
EX-99.1 2 d846583dex991.htm EX-99.1 Exhibit 99.1 BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview – Enrolled first NSCLC patient with KRAS mutation in phase 2 KRAS mutant or squamous histology NSCLC trial based on encouraging clinical activity from ongoing phase 2 trial with goal of rapid advancement to pivotal studies – – Initiating Phase 2 clinical trials in a |
|
| November 6, 2014 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update - Significant pipeline progress in clinical development with BIND-014 to be reported at EORTC-NCI-AACR meeting and selection of BIND-510 as new product candidate using AccurinTM platform - - Strengthened management and Board including Chief Medical Officer - - Research and Development |
|
| November 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d794252d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| November 6, 2014 |
BIND THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM EXHIBIT 10.1 BIND THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of BIND Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or |
|
| November 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| November 5, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| October 1, 2014 |
EX-4.2 EXHIBIT 4.2 BIND THERAPEUTICS, INC. INDENTURE Dated as of , 20 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. |
|
| October 1, 2014 |
EX-25.1 EXHIBIT 25.1 File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ¨ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its char |
|
| October 1, 2014 |
BIND THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENT EX-1.2 Exhibit 1.2 BIND THERAPEUTICS, INC. $40,000,000 COMMON STOCK SALES AGREEMENT October 1, 2014 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: BIND Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, |
|
| October 1, 2014 |
BIND / BIND Therapeutics, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on October 1, 2014 Registration No. |
|
| October 1, 2014 |
EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF CONSOLIDATED RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK DIVIDENDS FOR THE YEARS ENDED DECEMBER 31, 2011, 2012 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2014. (dollars in thousands) Year Ended December 31, Six Months Ended June 30, 2011 2012 2013 2014 Fixed charges: Interest expense on indebtedness $ 444 $ 553 $ 483 $ 278 Non- |
|
| September 3, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or org |
|
| August 7, 2014 |
EXHIBIT 10.2 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 26 day of June, 2014, by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company (“Landlord”), and BIND THERAPEUTICS, INC., a Delaware corporation (“Tenant,” formerly known as Bind Biosciences, Inc.). RECITALS A. WHEREAS, Landlord and Tenant entered into that certai |
|
| August 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36072 BIN |
|
| August 7, 2014 |
EXHIBIT 10.1 BIND THERAPEUTICS, INC. October 24, 2013 Yurii Udaltsov, Cand. Sc. Re: Waiver of Director Compensation Dear Yurii: This letter agreement confirms the understanding of BIND Therapeutics, Inc. (the “Company”) that you desire to waive all compensation payable to you by the Company for your service as a member of the Company’s board of directors (the “Board”) or any committee of the Board |
|
| August 7, 2014 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Second Quarter 2014 Financial Results - Management to host conference call today at 8:30 a.m. ET - Cambridge, MA, August 7, 2014 — BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the second quarter ended June |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or o |
|
| July 2, 2014 |
Termination of a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| May 28, 2014 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or org |
|
| May 8, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or orga |
|
| May 8, 2014 |
EX-99.1 2 d721756dex991.htm EX-99.1 Exhibit 99.1 BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan - BIND to expand trial program to evaluate BIND-014 in NSCLC with KRAS mutations - - Management to host conference call today at 8:30 am ET - Cambridge, MA, May 8, 2014 — BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine |
|
| May 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d709297d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com |
|
| April 15, 2014 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 15, 2014 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 4, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| March 25, 2014 |
S-8 As filed with the Securities and Exchange Commission on March 25, 2014 Registration No. |
|
| March 25, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or o |
|
| March 25, 2014 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Management to host conference call today at 8:30 am ET Cambridge, MA, March 25, 2014 — BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter an |
|
| March 25, 2014 |
Subsidiaries of BIND Therapeutics, Inc.: EX-21.1 2 d636513dex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of BIND Therapeutics, Inc.: Name Jurisdiction of Organization BIND (RUS) LLC Russia BIND Biosciences Security Corporation Massachusetts |
|
| March 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 3, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation o |
|
| February 14, 2014 |
BINDQ / DNIB Unwind, Inc. / Polaris Venture Partners V, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BIND THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05548N107 (CUSIP Number) Polaris Partners 1000 Winter Street, Suite 3350 Waltham, MA 02451 Gunderson Dettmer Stough Villeneuve Franklin & Hachig |
|
| February 10, 2014 |
BINDQ / DNIB Unwind, Inc. / Flagship Ventures Fund 2004 L P - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No.) BIND Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05548N107 (CUSIP Number) December 31, 2013 (Date of |
|
| February 6, 2014 |
BINDQ / DNIB Unwind, Inc. / Arch Venture Fund VII LP - BIND THERAPEUTICS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIND Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05548N107 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 17, 2014 |
BIND THERAPEUTICS, INC. 2006 STOCK INCENTIVE PLAN OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS EX-10.2 3 d661697dex102.htm EX-10.2 EXHIBIT 10.2 BIND THERAPEUTICS, INC. 2006 STOCK INCENTIVE PLAN OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS This OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS (the “Amendment”), is made effective as of January 13, 2014, by and between BIND Therapeutics, Inc., a Delaware corporation (the “Company”), and Greg Berk (the “Participant”). Except as set forth in this Am |
|
| January 17, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2014 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| January 17, 2014 |
EX-10.1 EXHIBIT 10.1 CONTRACTOR/CONSULTANT: n Gregory Berk BIND CONTACT: n Scott Minick EFFECTIVE DATE: n January 15, 2014 CONSULTING AGREEMENT This Consulting Agreement (together with its attachments, this “Agreement”) made as of the date written above (the “Effective Date”) is between BIND Therapeutics, Inc., a Delaware corporation having an address at 325 Vassar St, Cambridge, MA 02139; (“BIND” |
|
| January 7, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2013 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation o |
|
| December 12, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2013 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation o |
|
| December 12, 2013 |
EX-10.1 Exhibit 10.1 BIND Therapeutics, Inc. 325 Vassar Street Cambridge, MA 02139 www.bindtherapeutics.com phone 617.491.3400 fax 617.491.0351 December 9, 2013 Jerry Murry VP Small Molecule Process & Product Development Amgen, Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 Re: Amendment No. 1 to the Amended and Restated License Agreement by and between BIND Therapeutics, Inc. (“BIND”) a |
|
| November 5, 2013 |
EX-99.1 Exhibit 99.1 BIND Therapeutics Reports Third Quarter 2013 Financial Results Management to host conference call today at 8:30 am ET Cambridge, MA, November 5, 2013 — BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the three-month period ended Septem |
|
| November 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 d604261d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| November 5, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2013 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or |
|
| October 4, 2013 |
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-2 Exhibit 2 Execution Version FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Fourth Amended and Restated Investors’ Rights Agreement dated as of November 7, 2011 (this “Agreement”), is made by and among BIND Biosciences, Inc. |
|
| October 4, 2013 |
EX-1 Exhibit 1 August 17, 2013 BIND Therapeutics, Inc. 325 Vassar Street Cambridge, MA 02139 CREDIT SUISSE SECURITIES (USA) LLC, COWEN AND COMPANY, LLC, As Representatives of the Several Underwriters, c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue, New York, NY 10010-3629 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, NY 10022 Dear Sirs: As an inducement to the |
|
| October 4, 2013 |
BIND / BIND Therapeutics, Inc. / RUSNANO - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BIND THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05548N107 (CUSIP Number) Open Joint Stock Company “RUSNANO” Prospect 60-letiya Oktyabrya 10a 117036 Moscow Russian Federation +7 |
|
| October 3, 2013 |
EX-99.3 EXHIBIT 99.3 LIMITED POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Raffaele G. Fazio as the undersigned’s true and lawful attorney-in-fact, with full power of substitution, for and in the name, place and stead of the undersigned, in any and all capacities, to: 1) prepare, execute in the undersigned’s name and on the undersigned’s beh |
|
| October 3, 2013 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G, dated October 3, 2013, with respect to the shares of BIND Therapeutics, Inc., Common Stock, $.0001 par value, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securit |
|
| October 3, 2013 |
EX-99.2 3 d607314dex992.htm EX-99.2 EXHIBIT 99.2 AUTHORIZATION KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Raffaele G. Fazio (the “Agent”) as an authorized agent and signatory to act on behalf of the undersigned, in any and all capacities, to: 1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities an |
|
| October 3, 2013 |
BIND / BIND Therapeutics, Inc. / DHK Investments, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* BIND THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share 05548N107 (Title of class of securities) (CUSIP number) September 25, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| September 25, 2013 |
EX-3.1 EXHIBIT 3.1 RESTATED CERTIFICATE OF INCORPORATION OF BIND THERAPEUTICS, INC. (originally incorporated as BIND Biosciences, Inc. on May 19, 2006) FIRST: The name of the Corporation is BIND Therapeutics, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street in the City of Wilmington, County of New Castle, Zip Code 19801. The name of its |
|
| September 25, 2013 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2013 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36072 56-2596148 (State or other jurisdiction of incorporation or or |
|
| September 25, 2013 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BIND THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCED |
|
| September 20, 2013 |
Prospectus Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-190566 PROSPECTUS 4,700,000 Shares Common Stock This is the initial public offering of our common stock. Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for listing on the NASDAQ Global Select Market under the symbol “BIND.” The underwriters have an op |
|
| September 20, 2013 |
Form S-8 As filed with the Securities and Exchange Commission on September 20, 2013 Registration No. |
|
| September 20, 2013 |
FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated September 19, 2013 Relating to Preliminary Prospectus dated September 19, 2013 Registration No. |
|
| September 19, 2013 |
Amendment No 4 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on September 19, 2013 Registration No. |
|
| September 17, 2013 |
CORRESP Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010-3629 Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 September 17, 2013 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 17, 2013 |
CORRESP BIND THERAPEUTICS, INC. 325 Vassar Street Cambridge, Massachusetts 02139 September 17, 2013 VIA EDGAR Transmission Jeffrey P. Riedler Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: BIND Therapeutics, Inc. Registration Statement on Form S-1 Filed August 12, 2013 File No. 333-190566 Dear Mr. Riedler: In a |
|
| September 16, 2013 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 56-2596148 (State of incorporation or organization) (I.R.S. Employer Identification No.) 325 Vassar St |
|
| September 5, 2013 |
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.2 Exhibit 4.2 Execution Version FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Fourth Amended and Restated Investors’ Rights Agreement dated as of November 7, 2011 (this “Agreement”), is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser,” and collectively, the “Purchasers”); the pers |
|
| September 5, 2013 |
EX-10.12 Exhibit 10.12 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Ver. EQ.9/9/02 TLO: ARS MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENT TABLE OF CONTENTS R E C I T A L |
|
| September 5, 2013 |
BIND THERAPEUTICS, INC. 2013 INCENTIVE AWARD PLAN ARTICLE 1. EX-10.2 Exhibit 10.2 BIND THERAPEUTICS, INC. 2013 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the BIND Therapeutics, Inc. 2013 Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of BIND Therapeutics, Inc. (the “Company”) by linking the individual interests of the members of the Board, Employees, and Consu |
|
| September 5, 2013 |
CONSULTING AGREEMENT (Robert S. Langer, Jr.) EX-10.5 Exhibit 10.5 CONSULTING AGREEMENT (Robert S. Langer, Jr.) This Consulting Agreement dated as of October 31, 2006 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Robert S. Langer, Jr. (the “Consultant”). WHEREAS, the Company and the Consultant desire to enter into a Consulting Agreement as provided herein (the “Agreement”). NOW, |
|
| September 5, 2013 |
AMENDED AND RESTATED CONSULTING AGREEMENT (Omid Farokhzad) EX-10.6 Exhibit 10.6 AMENDED AND RESTATED CONSULTING AGREEMENT (Omid Farokhzad) This Amended and Restated Consulting Agreement dated as of July 12, 2007 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Omid Farokhzad (the “Consultant”). WHEREAS, the Company and the Consultant are parties to a Consulting Agreement dated as of October 31, |
|
| September 5, 2013 |
EX-10.9 Exhibit 10.9 BIND BIOSCIENCES, INC. March 20, 2013 Dr. Gregory Berk 332 South McCadden Place Los Angeles, California 90020 Re: Employment Terms Dear Greg: BIND Biosciences, Inc. (the “Company”), is pleased to offer you full-time employment as the Company’s Chief Medical Officer. You will be responsible for such duties as are normally associated with such position or as otherwise determined |
|
| September 5, 2013 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIND BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) BIND Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. Th |
|
| September 5, 2013 |
[—] Shares BIND Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 [—] Shares BIND Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT [—], 2013 CREDIT SUISSE SECURITIES (USA) LLC, COWEN AND COMPANY, LLC, As Representatives of the Several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue, New York, N.Y. 10010-3629 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, N.Y. 10022 Dear Sirs: 1. Introduc |
|
| September 5, 2013 |
EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK THIS CERTIFICATE IS TRANSFERABLE IN CANTON, MA, JERSEY CITY, NJ AND COLLEGE STATION, TX Certificate Number ZQ00000000 BIND THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sam |
|
| September 5, 2013 |
EX-10.11 Exhibit 10.11 June 3, 2007 Jeff Hrkach, PhD. 19 Diana Lane Lexington, MA 02421 Dear Jeff, It is with great pleasure that I offer you employment with BIND Biosciences, Inc. (“BIND” or “the Company”). Your initial position will be Vice President of Pharmaceutical Sciences reporting to me. In addition to performing duties and responsibilities associated with the position above, from time-to- |
|
| September 5, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.10 Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of June, 2013 is entered into by BIND Therapeutics, Inc. (f/k/a BIND Biosciences, Inc.), a Delaware corporation (the “Company”), and Daniel S. Lynch, an individual residing at 7 Calhoun Drive, Greenwich, Connecticut 06831 (the “Executive”). WHEREAS, |
|
| September 5, 2013 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 5, 2013 Registration No. |
|
| September 5, 2013 |
EX-10.7 Exhibit 10.7 January 11, 2010 Mr. Scott Minick 69 Wellington Avenue San Anselmo, CA 94960 Re: Employment Offer Letter Dear Scott: I am pleased to provide you with the terms and conditions of your anticipated employment by BIND Biosciences, Inc. (the “Company” or “BIND”). The following sets forth the terms and conditions of our offer of employment to you. 1. Position. (a) You will be the Pr |
|
| September 5, 2013 |
BIND THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM EX-10.3 Exhibit 10.3 BIND THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of BIND Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be |
|
| September 5, 2013 |
FOURTH AMENDED AND RESTATED VOTING AGREEMENT EX-4.6 Exhibit 4.6 FOURTH AMENDED AND RESTATED VOTING AGREEMENT This Fourth Amended and Restated Voting Agreement dated as of November 7, 2011 (this “Agreement”) is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser” and collectively, the “Purchasers”); Omid Farokhzad, Paul Goldenheim and Robert S. Lang |
|
| August 30, 2013 |
Response Letter FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: BIND Therapeutics, Inc. |
|
| August 28, 2013 |
EX-3.4 2 d579945dex34.htm EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF BIND THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 |
|
| August 28, 2013 |
EX-10.12 Exhibit 10.12 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Ver. EQ.9/9/02 TLO: ARS MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENT TABLE OF CONTENTS R E C I T A L |
|
| August 28, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT EX-10.15 Exhibit 10.15 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXECUTION COPY AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is effective as of January 7, 2013 (th |
|
| August 28, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT EX-10.17 Exhibit 10.17 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FINAL VERSION AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”), effective as of 19 April, 2013 (the “E |
|
| August 28, 2013 |
EX-10.14 Yale Confidential Exhibit 10.14 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT (the “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under a |
|
| August 28, 2013 |
S-1/A Amendment No 2 Table of Contents As filed with the Securities and Exchange Commission on August 28, 2013 Registration No. |
|
| August 28, 2013 |
AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENT EX-10.16 7 d579945dex1016.htm EX-10.16 Exhibit 10.16 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL EXECUTION COPY AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENT This Amended and Restated Research, O |
|
| August 28, 2013 |
EXCLUSIVE LICENSE AGREEMENT THE JOHNS HOPKINS UNIVERSITY BIND BIOSCIENCES, INC. JHU Ref: # [***] EX-10.13 4 d579945dex1013.htm EX-10.13 Exhibit 10.13 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY & BIND BIOSCIENCES, INC. JHU Ref: # [***] *** Certain inform |
|
| August 20, 2013 |
FORM OF INDEMNIFICATION AGREEMENT EX-10.4 4 d579945dex104.htm EX-10.4 EXHIBIT 10.4 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [ ] [ ], 20[ ], by and between BIND Therapeutics, Inc. (the “Company”) and [ ] (“Indemnitee”). RECITALS WHEREAS, the Company values Indemnitee’s service to the Company as a director or officer and desires that Indemnitee continue to ser |
|
| August 20, 2013 |
EX-3.4 3 d579945dex34.htm EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BY-LAWS OF BIND THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING |
|
| August 20, 2013 |
EX-3.3 2 d579945dex33.htm EX-3.3 EXHIBIT 3.3 RESTATED CERTIFICATE OF INCORPORATION OF BIND THERAPEUTICS, INC. (originally incorporated as BIND Biosciences, Inc. on May 19, 2006) FIRST: The name of the Corporation is BIND Therapeutics, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street in the City of Wilmington, County of New Castle, Zip C |
|
| August 20, 2013 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on August 20, 2013 Registration No. |
|
| August 19, 2013 |
CORRESP 1 filename1.htm John Hancock Tower, 20th Floor 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM /AFFILIATE OFFICES Abu Dhabi Milan Barcelona Moscow Beijing Munich Boston New Jersey Brussels New York FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: BIND Therapeutics, Inc. 325 Vassar Street Cambridg |
|
| August 12, 2013 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2013 Registration No. |
|
| August 12, 2013 |
EX-10.12 Exhibit 10.12 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Ver. EQ.9/9/02 TLO: ARS MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENT TABLE OF CONTENTS R E C I T A L |
|
| August 12, 2013 |
CONSULTING AGREEMENT (Robert S. Langer, Jr.) EX-10.5 Exhibit 10.5 CONSULTING AGREEMENT (Robert S. Langer, Jr.) This Consulting Agreement dated as of October 31, 2006 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Robert S. Langer, Jr. (the “Consultant”). WHEREAS, the Company and the Consultant desire to enter into a Consulting Agreement as provided herein (the “Agreement”). NOW, |
|
| August 12, 2013 |
AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENT EX-10.16 Exhibit 10.16 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL EXECUTION COPY AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENT This Amended and Restated Research, Option and License Agreement (t |
|
| August 12, 2013 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIND BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) BIND Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. Th |
|
| August 12, 2013 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.10 Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of June, 2013 is entered into by BIND Therapeutics, Inc. (f/k/a BIND Biosciences, Inc.), a Delaware corporation (the “Company”), and Daniel S. Lynch, an individual residing at 7 Calhoun Drive, Greenwich, Connecticut 06831 (the “Executive”). WHEREAS, |
|
| August 12, 2013 |
Subsidiaries of BIND Therapeutics, Inc.: EX-21.1 Exhibit 21.1 Subsidiaries of BIND Therapeutics, Inc.: Name Jurisdiction of Organization BIND (RUS) LLC Russia BIND Biosciences Security Corporation Massachusetts |
|
| August 12, 2013 |
EX-4.4 Exhibit 4.4 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SA |
|
| August 12, 2013 |
BIND BIOSCIENCES, INC. 2006 Stock Incentive Plan EX-10.1 Exhibit 10.1 BIND BIOSCIENCES, INC. 2006 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for BIND Biosciences, Inc., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporations w |
|
| August 12, 2013 |
FOURTH AMENDED AND RESTATED VOTING AGREEMENT EX-4.6 Exhibit 4.6 FOURTH AMENDED AND RESTATED VOTING AGREEMENT This Fourth Amended and Restated Voting Agreement dated as of November 7, 2011 (this “Agreement”) is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser” and collectively, the “Purchasers”); Omid Farokhzad, Paul Goldenheim and Robert S. Lang |
|
| August 12, 2013 |
AMENDED AND RESTATED CONSULTING AGREEMENT (Omid Farokhzad) EX-10.6 11 d555506dex106.htm EX-10.6 Exhibit 10.6 AMENDED AND RESTATED CONSULTING AGREEMENT (Omid Farokhzad) This Amended and Restated Consulting Agreement dated as of July 12, 2007 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Omid Farokhzad (the “Consultant”). WHEREAS, the Company and the Consultant are parties to a Consulting Agre |
|
| August 12, 2013 |
EXCLUSIVE LICENSE AGREEMENT THE JOHNS HOPKINS UNIVERSITY BIND BIOSCIENCES, INC. JHU Ref: # [***] EX-10.13 Exhibit 10.13 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY & BIND BIOSCIENCES, INC. JHU Ref: # [***] *** Certain information on this page has been om |
|
| August 12, 2013 |
EX-10.11 Exhibit 10.11 June 3, 2007 Jeff Hrkach, PhD. 19 Diana Lane Lexington, MA 02421 Dear Jeff, It is with great pleasure that I offer you employment with BIND Biosciences, Inc. (“BIND” or “the Company”). Your initial position will be Vice President of Pharmaceutical Sciences reporting to me. In addition to performing duties and responsibilities associated with the position above, from time-to- |
|
| August 12, 2013 |
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.2 Execution Version FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Fourth Amended and Restated Investors’ Rights Agreement dated as of November 7, 2011 (this “Agreement”), is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser,” and collectively, the “Purchasers”); the persons and |
|
| August 12, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT Exhibit 10.15 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXECUTION COPY AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is effective as of January 7, 2013 (the “Effect |
|
| August 12, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT EX-10.17 Exhibit 10.17 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FINAL VERSION AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”), effective as of 19 April, 2013 (the “E |
|
| August 12, 2013 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.18 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT, dated as of June 12, 2013 (the “Effective Date”), is entered into by and between BIND THERAPEUTICS, INC., a Delaware corporation, and each of subsidiaries that execute a Joinder Agreement from time to time, (individually, a “Borrower” and, collectively, the “Borrowers”), and HERCUL |
|
| August 12, 2013 |
BY-LAWS BIND BIOSCIENCES, INC. EX-3.2 Exhibit 3.2 BY-LAWS OF BIND BIOSCIENCES, INC. Section 1 CERTIFICATE OF INCORPORATION AND BY-LAWS 1.1 These by-laws are subject to the certificate of incorporation of the corporation. In these by-laws, references to the certificate of incorporation and by-laws mean the provisions of the certificate of incorporation and the by-laws as are from time to time in effect. Section 2 OFFICES 2.1 Reg |
|
| August 12, 2013 |
EX-10.19 Exhibit 10.19 LEASE by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company and BIND BIOSCIENCES, INC., a Delaware corporation BMR form dated 3/16/11 LEASE THIS LEASE (this “Lease”) is entered into as of this 20th day of July, 2011 (the “Execution Date”), by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company (“Landlord”), and BIND BIOSCIENCE |
|
| August 12, 2013 |
EX-4.5 Exhibit 4.5 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SA |
|
| August 12, 2013 |
EX-4.3 Exhibit 4.3 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR HOLDER, SATISFACTORY TO CO |
|
| August 12, 2013 |
EX-10.8 Exhibit 10.8 CONSULTANT: ¨ Greg Berk BIND CONTACT: ¨ Scott Minick EFFECTIVE DATE: ¨ May 15, 2012 CONSULTING AGREEMENT This Consulting Agreement (together with its attachments, this “Agreement”) made as of the date written above (the “Effective Date”) is between BIND Biosciences, Inc., a Delaware corporation having an address at 325 Vassar St, Cambridge, MA 02139; (“BIND”) and the consultan |
|
| August 12, 2013 |
EX-10.7 Exhibit 10.7 January 11, 2010 Mr. Scott Minick 69 Wellington Avenue San Anselmo, CA 94960 Re: Employment Offer Letter Dear Scott: I am pleased to provide you with the terms and conditions of your anticipated employment by BIND Biosciences, Inc. (the “Company” or “BIND”). The following sets forth the terms and conditions of our offer of employment to you. 1. Position. (a) You will be the Pr |
|
| August 12, 2013 |
EX-10.9 14 d555506dex109.htm EX-10.9 Exhibit 10.9 BIND BIOSCIENCES, INC. March 20, 2013 Dr. Gregory Berk 332 South McCadden Place Los Angeles, California 90020 Re: Employment Terms Dear Greg: BIND Biosciences, Inc. (the “Company”), is pleased to offer you full-time employment as the Company’s Chief Medical Officer. You will be responsible for such duties as are normally associated with such positi |
|
| August 12, 2013 |
EX-10.14 Yale Confidential Exhibit 10.14 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT (the “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under a |
|
| August 2, 2013 |
DRS/A 1 filename1.htm Table of Contents As submitted to the Securities and Exchange Commission confidentially on August 2, 2013 as Amendment No.1 to the confidential submission As filed with the Securities and Exchange Commission on , 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 B |
|
| August 2, 2013 |
EX-10.9 3 filename3.htm Exhibit 10.9 BIND BIOSCIENCES, INC. March 20, 2013 Dr. Gregory Berk 332 South McCadden Place Los Angeles, California 90020 Re: Employment Terms Dear Greg: BIND Biosciences, Inc. (the “Company”), is pleased to offer you full-time employment as the Company’s Chief Medical Officer. You will be responsible for such duties as are normally associated with such position or as othe |
|
| August 2, 2013 |
FOURTH AMENDED AND RESTATED VOTING AGREEMENT EX-4.6 Exhibit 4.6 FOURTH AMENDED AND RESTATED VOTING AGREEMENT This Fourth Amended and Restated Voting Agreement dated as of November 7, 2011 (this “Agreement”) is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser” and collectively, the “Purchasers”); Omid Farokhzad, Paul Goldenheim and Robert S. Lang |
|
| August 2, 2013 |
CORRESP John Hancock Tower, 20th Floor 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1. |
|
| June 28, 2013 |
EX-10.12 Exhibit 10.12 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Ver. EQ.9/9/02 TLO: ARS MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENT TABLE OF CONTENTS R E C I T A L |
|
| June 28, 2013 |
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.2 Exhibit 4.2 Execution Version FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Fourth Amended and Restated Investors’ Rights Agreement dated as of November 7, 2011 (this “Agreement”), is made by and among BIND Biosciences, Inc., a Delaware corporation (the “Company”); the persons and entities listed on Schedule A (each a “Purchaser,” and collectively, the “Purchasers”); the pers |
|
| June 28, 2013 |
EXCLUSIVE LICENSE AGREEMENT THE JOHNS HOPKINS UNIVERSITY BIND BIOSCIENCES, INC. JHU Ref: # [***] EX-10.13 Exhibit 10.13 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY & BIND BIOSCIENCES, INC. JHU Ref: # [***] *** Certain information on this page has been om |
|
| June 28, 2013 |
BIND BIOSCIENCES, INC. 2006 Stock Incentive Plan EX-10.1 Exhibit 10.1 BIND BIOSCIENCES, INC. 2006 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for BIND Biosciences, Inc., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporations w |
|
| June 28, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT EX-10.17 Exhibit 10.17 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FINAL VERSION AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”), effective as of 19 April, 2013 (the “E |
|
| June 28, 2013 |
Subsidiaries of BIND Therapeutics, Inc.: EX-21.1 Exhibit 21.1 Subsidiaries of BIND Therapeutics, Inc.: Name Jurisdiction of Organization BIND (RUS) LLC Russia BIND Biosciences Security Corporation Massachusetts |
|
| June 28, 2013 |
EX-10.11 Exhibit 10.11 June 3, 2007 Jeff Hrkach, PhD. 19 Diana Lane Lexington, MA 02421 Dear Jeff, It is with great pleasure that I offer you employment with BIND Biosciences, Inc. (“BIND” or “the Company”). Your initial position will be Vice President of Pharmaceutical Sciences reporting to me. In addition to performing duties and responsibilities associated with the position above, from time-to- |
|
| June 28, 2013 |
EX-10.8 Exhibit 10.8 CONSULTANT: ¨ Greg Berk BIND CONTACT: ¨ Scott Minick EFFECTIVE DATE: ¨ May 15, 2012 CONSULTING AGREEMENT This Consulting Agreement (together with its attachments, this “Agreement”) made as of the date written above (the “Effective Date”) is between BIND Biosciences, Inc., a Delaware corporation having an address at 325 Vassar St, Cambridge, MA 02139; (“BIND”) and the consultan |
|
| June 28, 2013 |
EX-4.4 Exhibit 4.4 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SA |
|
| June 28, 2013 |
EX-4.5 Exhibit 4.5 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SA |
|
| June 28, 2013 |
AMENDED AND RESTATED LICENSE AGREEMENT EX-10.15 Exhibit 10.15 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXECUTION COPY AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is effective as of January 7, 2013 (th |
|
| June 28, 2013 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIND BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) BIND Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. Th |
|
| June 28, 2013 |
CONSULTING AGREEMENT (Robert S. Langer, Jr.) EX-10.5 Exhibit 10.5 CONSULTING AGREEMENT (Robert S. Langer, Jr.) This Consulting Agreement dated as of October 31, 2006 (this “Agreement”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Robert S. Langer, Jr. (the “Consultant”). WHEREAS, the Company and the Consultant desire to enter into a Consulting Agreement as provided herein (the “Agreement”). NOW, |
|
| June 28, 2013 |
Form S-1 Table of Contents As submitted to the Securities and Exchange Commission confidentially on June 28, 2013 As filed with the Securities and Exchange Commission on , 2013 Registration No. |
|
| June 28, 2013 |
EX-10.14 Yale Confidential Exhibit 10.14 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT (the “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under a |
|
| June 28, 2013 |
EX-10.19 Exhibit 10.19 LEASE by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company and BIND BIOSCIENCES, INC., a Delaware corporation BMR form dated 3/16/11 LEASE THIS LEASE (this “Lease”) is entered into as of this 20th day of July, 2011 (the “Execution Date”), by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company (“Landlord”), and BIND BIOSCIENCE |
|
| June 28, 2013 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT EX-10.18 Exhibit 10.18 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT, dated as of June 12, 2013 (the “Effective Date”), is entered into by and between BIND THERAPEUTICS, INC., a Delaware corporation, and each of subsidiaries that execute a Joinder Agreement from time to time, (individually, a “Borrower” and, collectively, the “Borrowers”), a |
